Happy to see double digit PAT numbers. I hope the tides turn soon.
If anyone has a chance to note down the concall details, pls do enlighten what management has to say about the result and (I know these folks are always shy of giving guidance) possible guidance.
Invested. Bias.
Thank You for the clarification Sir
Despite of the good result why the stock price is falling?
Btw, Mukesh on twitter is the best handle when it comes to forensics.
just saw a post on Twitter, there is apparently a gap between Consolidated and sum of the standalone on Twitter
is this true and possible, and if yes, then what can explain ?
More interesting stuff
Q2 FY2025 Conference call Highlights:
Opening Remarks:
Revenue increase 19% YoY.
EBIDTA increase 104% YoY.
PAT increase 93% YoY.
CDO/CDMO Ambernath facility started from Q4 FY2024 for finished formulations. 70KL.
Manufacturing block (E block) at Lote Parshuram, which will increase total capacity from 597 KL (76% utilization, optimum) to 1,020 KL by Q3 FY25. It will take 1.5 to 2 years to take reach max. capacity.
Guidance:
Confident of 20% Revenue growth with high margin.
Revenue target of 1000cr. by FY2027 with high margin. Very conservative guidance.
CDO/CDMO to diversify revenue stream.
Margin guidance is 30 to 34% on yearly base due to new products.
Margin :
Backward integration helps in increase in margin. Many products manufactured up to 8 steps backward integrated.
Regulated markets have higher margin.
New products will be added in next quarter, which will have slight dip in margin due to first roll out in semi regulated margin and then to regulated market.
Cancer oral detection kit: filing patent for many countries, expected to start clinical trails. Revenue may come after 3 years.
CDO/CDMO opportunity:
Full effect will be in 2 years. In next 3 years, should contribute to 20% of revenue.
No capex, next wave will be in Patalgana after 2 to 3 years.
Once DSM project complete, bigger opportunity may come.
Margins will be similar. Formulation will have higher margin.
China:
Supriya do not produce any product which is produced in INDIA. They compete with China, as Chinese plants do not have GMP or any certification. Do not negotiate for price as Supriya is GMP, USFDA certified plant.
Others:
52% revenue from regulated market, remaining from semi regulated market and domestic market.
Diversify product portfolio and not dependent on any key raw material. Raw material Available cheaply and widely available.
H2 will be better then H1 on overall basis.
Latin American market is improving and will continue progress as registration continue.
H2 will be better then H1 on overall basis.
Latin American market is improving and will continue progress as registration continue.
D: Invested
As envisaged by me in my previous post, I was expecting muted earnings and net profits in Q2 FY25 and it seems that those concerns have played out.
With massive Capex plans in next 4-5 years, there could be negative impact on ROCE over next few years.
Following report highlights both positives and negatives about Coal India in near to medium term.
Disclosure: Trimmed the position during FY24-25 but still holding for Dividend Yield. Also optimistic about further increase in coal production volumes though net profit growth could be muted. I might be wrong in my analysis. I am not a SEBI registered analyst.
Like I show on many highway hotel vadilal deepfreeze, new board, i think on highway hotel if we are with kids and they want ice cream then nobody going for any specific brand we just going to available and purchase, and many new stores I see new vadilal deepfreeze, hocco and havemore ahead of vadilal but valuation wise I don’t see much downside
(post deleted by author)